AC BioScience, a Biopôle-based biotech company, is pleased to announce a breakthrough discovery with its new immunomodulating molecule ACB2112 and the appointment of Dr. Annette Ives as the new Chief Scientific Officer (CSO).
Resulting from years of intensive research into its two legacy oncology molecules, the company has achieved a breakthrough discovery with its new immunomodulating molecule ACB2112 poised to expand significantly the patient pool that will respond to treatment in colorectal cancer.
Andreas Schläpfer, Chairman of the Board and Co-founder of AC BioScience
Current immunotherapy regimens are ineffective at treating most colorectal cancer (CRC) patients. As a result of immune escape, 85% of CRC patients who are MSS/MSI-L do not respond to Immune Checkpoint Inhibitor (ICI) therapy. ACB2112 is effectively targeting the main mechanisms of immune escape and achieved exceptional tumor growth reduction in vivo combination treatments with ICIs.
The company now focuses its entire efforts on further validating the effectiveness and safety of ACB2112 and on bringing the molecule to the clinic. Andreas Schläpfer, Chairman of the Board and Co-founder of AC BioScience, said: “I am delighted that this molecule could render immunotherapy effective for all colorectal cancer patients and could become a new standard of care for patients with colorectal cancer. On this same occasion, I am also very pleased to announce the appointment of Dr. Annette Ives as our new Chief Scientific Officer. She has been a senior scientist since the inception of our company and was instrumental in the development of our breakthrough molecule ACB2112”.
Read Press Release